Medicine
Benicar HCT 25 mg/40 mg tablet
Benicar HCT 25 mg/40 mg tablet is a prescription medicine containing Hydrochlorothiazide and Olmesartan for oral use, marketed by Cosette Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 20-25ºC (68-77ºF).
Key facts
- Active ingredient (INN)
- Hydrochlorothiazide and Olmesartan
- Brand
- Benicar HCT
- Strength
- 25 mg/40 mg
- Dosage form
- Tablet
- Route
- Oral
- Packs
- 30 tablets
- Marketing authorisation holder
- Cosette Pharmaceuticals
- Manufacturer
- Cosette Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Store at 20-25ºC (68-77ºF).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 1 September 2022
- Identifiers
- RxCUI 403853, 403854, 403855 +3DailyMed set ID 881a1c32-c209-4038-9c5e-c5e46c6e0546, a90915ca-f9d3-4fff-8370-d5dc4cdfc521NDC 0713-0865, 0713-0945Application NDA021532
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 30 tablet, film coated in 1 bottle, plastic | 0713-0865-30 | Cosette Pharmaceuticals | 1 September 2022 |
| 30 tablet, film coated in 1 bottle, plastic | 0713-0945-30 | Cosette Pharmaceuticals | 1 April 2026 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 5 June 2003 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Hydrochlorothiazide and Olmesartan 25 mg/40 mg tablet.
Other strengths and forms of Hydrochlorothiazide and Olmesartan
Clinical summary
Hydrochlorothiazide and Olmesartan is a fixed-dose combination of an angiotensin 2 receptor blocker and a thiazide diuretic indicated for the treatment of hypertension, to lower blood pressure, among other approved uses. MedsAcross supplies Hydrochlorothiazide and Olmesartan for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Hydrochlorothiazide and OlmesartanFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Benicar HCT prescribing information (Cosette Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
Need Benicar HCT 25 mg/40 mg tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.